CoreAge Rx combines an online medical assessment with prescription fulfillment and continuing provider access. Its semaglutide product page currently advertises $99 per month, while compounded tirzepatide is listed at $149 per month. Both pages say there is no separate membership fee. Those are provider-advertised offers, rather than an independent test of the clinical service.
The appeal is an easy-to-read monthly bill. The decision still depends on medical eligibility, the exact preparation a clinician prescribes, and the terms shown at checkout. A lower advertised price does not make a compounded medicine equivalent to an FDA-approved branded product.
Offer highlights
- Advertised same price at every dose
- Medication and supplies advertised together
- Ongoing provider access through the platform
Ask before paying
- What makes a compounded prescription appropriate for me?
- Which pharmacy will fill my prescription?
- When does my order become non-refundable?
Products, pricing & billing
The two weight-loss product pages list medication, supplies, and shipping as part of the offer and advertise the same price at each dose. Check the final prescription and order summary for the treatment, amount supplied, billing interval, and any consultation charge. The homepage contains other general starting-price language, so the product page and checkout are more useful than an isolated promotional headline.
CoreAge also lists semaglutide microdosing at $149 per month, NAD+ injectable therapy at $93 per month, and sermorelin at $99 per month. These are different therapies with different evidence and purposes. We do not count NAD+ or sermorelin as proven substitutes for approved obesity medicines.
The refund policy is a material tradeoff. Once an order is approved and sent to the pharmacy, it becomes non-refundable. There is also a 30-day cutoff after purchase, even if an order has not shipped. When someone is medically ineligible, the policy describes refunding the eligible treatment portion while retaining an applicable $50–$100 consultation fee. Read the policy before paying, especially if you still need documents or answers.
Care and follow-up
The public process starts with treatment selection and a medical questionnaire. A licensed clinician assesses suitability; an assessment does not guarantee a prescription. Video or other real-time communication may be required depending on state rules. If treatment is approved, a pharmacy prepares and dispenses the prescription.
Ask how to contact the prescribing clinician, what happens between refills, and who handles a delayed or warm shipment. Before using a vial, the pharmacy should provide written directions that identify the medicine, concentration, prescribed amount, and storage requirements. FDA has reported dosing errors with compounded GLP-1 products, so unclear instructions deserve a direct conversation with the clinician or pharmacist.
Our take
CoreAge is worth including on a self-pay shortlist when you want to compare a stated monthly compounded-medicine price with programs that charge membership and medication separately. Its refund deadlines deserve equal attention to its monthly rate. Confirm the complete cost and clinical rationale before enrolling.
We have not received treatment, independently inspected the dispensing pharmacy, or verified advertised patient outcomes. This review evaluates publicly available offer details. Branded semaglutide and tirzepatide trials cannot establish the effectiveness of a particular CoreAge compounded preparation. Bring the offer to your clinician and compare it with an available FDA-approved treatment.
Put the offer in context
Read the GLP-1 program comparison and complete cost guide to compare membership, medication, and recurring charges. The branded and compounded treatment guide explains the product distinctions.
Compare another model in our Ro review or Noom Med review.
Sources & offer details
Public information retrieved on October 1, 2026. Provider statements describe the advertised offer; they do not independently establish treatment outcomes.